Flazar Rabbani et al Serial No.: 08/978,635 Filed: November 25, 1997

Page 2 | Amendment Under 37 C.F.R. §1.115 (In Response

to the February 16, 1999 Office Action - August 16, 1999]

PLEASE AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:

In The Specification:

Page 1, line 1, insert the following:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. Patent Application Serial No. 08/574,443, filed on December 15, 1995, now abandoned.

Page 9, line 13, after "reimportation to the" and before "as snRNPs" change.

"cytoplasm" to -- nucleus -- .

Page 64, line 14, after "phosphate buffered" and before "to reconstitute" change "salint" to -- saline -- .

Page 81, line 7, after "i.e., a cell" and before "of processing RNA by" change "capable" to -- incapable -- .

Page 105, line 2, after "number of" and before "entities" change "procuct" to -- product -- .

Page 109, line 5, change the first word in this line before "synthesis" from "intracellar" to -- intracellular ---

Page 114, line 7, after "by which the" and before "agent binds" change "dislocation" to -- dislocation -- .

Page 129, line 7, change the penultimate word in this line from "shwon" to -- shown -- .

Elazar Rabbani et al. Senai No.: 08.978,635 Filed. November 25, 1997

Page 3 [Amendment Under 37 C.F.R. §1.115 (In Response to the February 16, 1999 Office Action - August 16, 1999]

Page 127, last line, change the first word in this line from "stepavidin" to -- streptavidin -- .

Page 134, lines 6, 9 and 10, change the spelling of "CNMAC" to -- CHENAC -- in all three instances.

Page 151, line 8, change the first word in this line from "complimentary" to -- complementary -- .

Page 159, line 11, delete the last word in this line "structures" which is duplicative of the previous word.

Page 180, line 8, after "assay of the" and before "of the U1" change "affect" to -- effect -- .

Page 181, line 4, after "CD8-coated" and before "Flasks" change $"(CELLectorTM"\ to\ --(CELLector^{TM}\ --\ .$

In The Claims:

Cancel claims 2-24.

Amend claims 246, 247 and 251 as follows:



246. (Amended) The process of claim 245, wherein said processing element comprises an RNA processing element selected from the group consisting of an intron, a polyadenylation signal, [and] a capping element, [or] and a combination of the foregoing.

247. (Amended) The process of claim 245, wherein said nucleic acid product is selected from the group consisting of antisense RNA, antisense DNA, sense RNA, sense DNA, a ribozyme, [and] a protein binding nucleic acid sequence, [or] and a combination of the foregoing.